ProStrakan Group / Archimedes Pharma merger inquiry

The CMA investigated the completed acquisition by ProStrakan Group Plc of Archimedes Pharma Limited.

Statutory timetable

Phase 1 date Action
1 December 2014 Decision published
14 November 2014 Decision announced
22 September 2014 Launch of merger inquiry
22 September 2014 Invitation to comment
5 August 2014 Initial enforcement order

Phase 1

CMA clearance decision

14 November 2014: The CMA has cleared the acquisition by ProStrakan Group Plc of Archimedes Pharma Limited. The full text of the decision is available below:

Invitation to comment: Now closed

22 September 2014: The Competition and Markets Authority (CMA) is considering whether it is or may be the case that this transaction has resulted in the creation of a relevant merger situation under the merger provisions of the Enterprise Act 2002 and, if so, whether the creation of that situation has resulted, or may be expected to result, in a substantial lessening of competition within any market or markets in the United Kingdom for goods or services.

Initial enforcement order

5 August 2014: The CMA served an initial enforcement order under section 72(2) of the Enterprise Act 2002 on ProStrakan Group Plc in relation to its completed acquisition of Archimedes Pharma Limited by the CMA. A copy of the order is below:

Amendments/consents granted:

Contact

Please send written representations about any competition or public interest to:

Suzanne van Scheijen
Competition and Markets Authority
Victoria House
37 Southampton Row
London
WC1B 4AD

Suzanne.VanScheijen@cma.gsi.gov.uk

Updates to this page

Published 9 December 2014